Onc.AI, a San Carlos, CA- and Waterloo, Canada-based digital health company developing a novel oncology care management solution, closed a $6M financing round.
The round was co-led by Blue Venture Fund and Accomplice, with participation from KdT Ventures, Digitalis Ventures and prominent angel investors, including: The Operator Network (Frederic Kerrest, Executive Vice Chairman, COO and Co-founder, Okta), Jonathan Fleming (Chairman of Onc.AI and multiple VC-backed life sciences companies), Dr. Chen Fong (Co-Chair of the Global Strategy Board at Creative Destruction Lab), and Dr. Stanley Marks (Chairman of UPMC Hillman Cancer Center).
The company intends to use the funds to expand its team in the Bay area and Waterloo region, and execute on its operating plan with the objective of demonstrating the capabilities of our clinical solutions at cancer centers and health systems.
Led by Akshay Nanduri, Co-founder and CEO, Onc.AI is a digital health company developing a precision oncology care management platform that aims to transform clinical decision making.
Its seasoned founding team includes operating executives, expert technologists and repeat successful entrepreneurs from market leaders in healthcare, AI, autonomous-driving and oncology. The company’s Advisory Board comprises leading researchers and medical oncologists, including Dr. Hugo Aerts, Director of the AI in Medicine Program at Harvard/BWH and Dr. George Simon, Executive Director of the Moffitt-Advent joint Clinical Research Unit.